Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1

Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139 · see citing works

Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation

Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609 · see citing works

Identification of a Primary Target of Thalidomide Teratogenicity

Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136 · see citing works

A mammalian protein targeted by G1-arresting rapamycin–receptor complex

Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053 · see citing works

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879 · see citing works

Phthalimide conjugation as a strategy for in vivo target protein degradation

Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760 · see citing works

Mechanism of auxin perception by the TIR1 ubiquitin ligase

Tan, X., Calderon-Villalobos, L. I. A., Sharon, M., Zheng, C., Robinson, C. V., Estelle, M., & Zheng, N. (2007) · Nature · doi:10.1038/nature05731 · Cited by 1,688 · see citing works

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583 · see citing works

Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein

Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577 · see citing works

Jasmonate perception by inositol-phosphate-potentiated COI1–JAZ co-receptor

Sheard, L. B., Tan, X., Mao, H., Withers, J., Ben-Nissan, G., Hinds, T. R., Kobayashi, Y., Hsu, F.-F., Sharon, M., Browse, J., et al. (2010) · Nature · doi:10.1038/nature09430 · Cited by 1,497 · see citing works

Auxin regulates SCFTIR1-dependent degradation of AUX/IAA proteins

Gray, W. M., Kepinski, S., Rouse, D. T., Leyser, O., & Estelle, M. A. (2001) · Nature · doi:10.1038/35104500 · Cited by 1,415 · see citing works

Catalytic in vivo protein knockdown by small-molecule PROTACs

Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356 · see citing works

Structure of Hæmoglobin: A Three-Dimensional Fourier Synthesis at 5.5-Å. Resolution, Obtained by X-Ray Analysis

Perutz, M. F., Rossmann, M. G., Cullis, A. F., Muirhead, H., Will, G., & North, A. C. T. (1960) · Nature · doi:10.1038/185416a0 · Cited by 1,351 · see citing works

Structural basis of PROTAC cooperative recognition for selective protein degradation

Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242 · see citing works

Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex

Yu, X., Yu, Y., Liu, B., Luo, K., Kong, W., Mao, P., & Yu, X.-F. (2003) · Science · doi:10.1126/science.1089591 · Cited by 1,194 · see citing works

Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide

Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141 · see citing works

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140 · see citing works

Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4

Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056 · see citing works

Twenty years on: the impact of fragments on drug discovery

Erlanson, D. A., Fesik, S. W., Hubbard, R. E., Jahnke, W., & Jhoti, H. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.109 · Cited by 1,000 · see citing works

Structure of the FKBP12-Rapamycin Complex Interacting with Binding Domain of Human FRAP

Choi, J., Chen, J., Schreiber, S. L., & Clardy, J. (1996) · Science · doi:10.1126/science.273.5272.239 · Cited by 933 · see citing works

Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1

Navia, M. A., Fitzgerald, P. M. D., McKeever, B. M., Leu, C., Heimbach, J. C., Herber, W. K., Sigal, I. S., Darke, P. L., & Springer, J. P. (1989) · Nature · doi:10.1038/337615a0 · Cited by 892 · see citing works

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS

Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863 · see citing works

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer

Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852 · see citing works

X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex

Griffith, J. P., Kim, J. L., Kim, E. E., Sintchak, M. D., Thomson, J. A., Fitzgibbon, M. J., Fleming, M. A., Caron, P. R., Hsiao, K., & Navia, M. A. (1995) · Cell · doi:10.1016/0092-8674(95)90439-5 · Cited by 834 · see citing works

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814 · see citing works

The evolution of thalidomide and its IMiD derivatives as anticancer agents

Bartlett, J. B., Dredge, K. S., & Dalgleish, A. G. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1323 · Cited by 811 · see citing works

Crystal structures of human calcineurin and the human FKBP12–FK506–calcineurin complex

Kissinger, C. R., Parge, H. E., Knighton, D. R., Lewis, C. T., Pelletier, L. A., Tempczyk, A., Kalish, V. J., Tucker, K. D., Showalter, R. E., Moomaw, E. W., et al. (1995) · Nature · doi:10.1038/378641a0 · Cited by 762 · see citing works

A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase

Matyskiela, M. E., Lu, G., Ito, T., Pagarigan, B., Lu, C.-C., Miller, K., Fang, W., Wang, N.-Y., Nguyen, D., Houston, J., et al. (2016) · Nature · doi:10.1038/nature18611 · Cited by 701 · see citing works

The Mechanism of Action of Cyclosporin A and FK506

Ho, S. N., Clipstone, N. A., Timmermann, L., Northrop, J. P., Graef, I. A., Fiorentino, D. F., Nourse, J., & Crabtree, G. R. (1996) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1996.0140 · Cited by 676 · see citing works

Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics

Schneekloth, A. R., Pucheault, M., Tae, H. S., & Crews, C. M. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.114 · Cited by 635 · see citing works

Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase

Petzold, G., Fischer, E. S., & Thomä, N. H. (2016) · Nature · doi:10.1038/nature16979 · Cited by 620 · see citing works

Modular PROTAC design for the degradation of oncogenic BCR-ABL

Lai, A. C., Toure, M., Hellerschmied, D., Salami, J., Jaime‐Figueroa, S., Ko, E., Hines, J., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507634 · Cited by 618 · see citing works

Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction

Buckley, D. L., Van Molle, I., Gareiss, P. C., Tae, H. S., Michel, J., Noblin, D. J., Jorgensen, W. L., Ciulli, A., & Crews, C. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja209924v · Cited by 569 · see citing works

Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs

Chamberlain, P. P., Lopez-Girona, A., Miller, K., Carmel, G., Pagarigan, B., Chie-Leon, B., Rychak, E., Corral, L. G., Ren, Y. J., Wang, M., et al. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2874 · Cited by 531 · see citing works

Modulators of Protein–Protein Interactions

Milroy, L.-G., Grossmann, T. N., Hennig, S., Brunsveld, L., & Ottmann, C. (2014) · Chemical Reviews · doi:10.1021/cr400698c · Cited by 497 · see citing works

Structure-Guided Design and Optimization of Small Molecules Targeting the Protein–Protein Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities

Galdeano, C., Gadd, M. S., Soares, P., Scaffidi, S., Molle, I. V., Birced, I., Hewitt, S. H., Dias, D. M. G., & Ciulli, A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5011258 · Cited by 424 · see citing works

RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis

Lipkowitz, S., & Weissman, A. M. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3120 · Cited by 415 · see citing works

Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras

Lebraud, H., Wright, D. J., Johnson, C. N., & Heightman, T. D. (2016) · ACS Central Science · doi:10.1021/acscentsci.6b00280 · Cited by 413 · see citing works

Protein Knockdown Using Methyl Bestatin−Ligand Hybrid Molecules: Design and Synthesis of Inducers of Ubiquitination-Mediated Degradation of Cellular Retinoic Acid-Binding Proteins

Itoh, Y., Ishikawa, M., Naito, M., & Hashimoto, Y. (2010) · Journal of the American Chemical Society · doi:10.1021/ja100691p · Cited by 404 · see citing works

Biophysics in drug discovery: impact, challenges and opportunities

Renaud, J., Chung, C., Danielson, U. H., Egner, U., Hennig, M., Hubbard, R. E., & Nar, H. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.123 · Cited by 388 · see citing works

Role of GTP Hydrolysis in Fission of Caveolae Directly from Plasma Membranes

Schnitzer, J. E., Oh, P., & McIntosh, D. P. (1996) · Science · doi:10.1126/science.274.5285.239 · Cited by 376 · see citing works

Small‐Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1α

Buckley, D. L., Gustafson, J. L., Van Molle, I., Roth, A. G., Tae, H. S., Gareiss, P. C., Jorgensen, W. L., Ciulli, A., & Crews, C. M. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201206231 · Cited by 302 · see citing works

Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals)

Schiedel, M., Herp, D., Hammelmann, S., Swyter, S., Lehotzky, A., Robaa, D., Oláh, J., Ovádi, J., Sippl, W., & Jung, M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01872 · Cited by 275 · see citing works

Interfacial inhibitors: targeting macromolecular complexes

Pommier, Y. G., & Marchand, C. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3404 · Cited by 260 · see citing works

Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1

Crew, A. P., Raina, K., Dong, H., Qian, Y., Wang, J., Vigil, D., Serebrenik, Y. V., Hamman, B. D., Morgan, A., Ferraro, C., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00635 · Cited by 257 · see citing works

Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation

Maniaci, C., Hughes, S. J., Testa, A., Chen, W., Lamont, D. J., Rocha, S., Alessi, D. R., Romeo, R., & Ciulli, A. (2017) · Nature Communications · doi:10.1038/s41467-017-00954-1 · Cited by 245 · see citing works

Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin

Jin, L., & Harrison, S. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.212504399 · Cited by 244 · see citing works

Potent and selective chemical probe of hypoxic signalling downstream of HIF-α hydroxylation via VHL inhibition

Frost, J., Galdeano, C., Soares, P., Gadd, M. S., Grzes, K. M., Ellis, L. C. J., Epemolu, O., Shimamura, S., Bantscheff, M., Grandi, P., et al. (2016) · Nature Communications · doi:10.1038/ncomms13312 · Cited by 242 · see citing works

Impact of linker length on the activity of PROTACs

Cyrus, K., Wehenkel, M., Choi, E.-Y., Han, H.-J., Lee, H., Swanson, H., & Kim, K.-B. (2010) · Molecular BioSystems · doi:10.1039/c0mb00074d · Cited by 232 · see citing works

Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy

Ottis, P., & Crews, C. M. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b01068 · Cited by 227 · see citing works

Paramyxoviruses SV5 and HPIV2 Assemble STAT Protein Ubiquitin Ligase Complexes from Cellular Components

Ulane, C. M., & Horvath, C. M. (2002) · Virology · doi:10.1006/viro.2002.1773 · Cited by 225 · see citing works

Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds

Chan, K.-H., Zengerle, M., Testa, A., & Ciulli, A. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01912 · Cited by 222 · see citing works

A “Click Chemistry Platform” for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation

Wurz, R. P., Dellamaggiore, K., Dou, H., Javier, N., LO, M. M. ‐., McCarter, J. D., Mohl, D. A., Sastri, C. E., Lipford, J. R., & Cee, V. J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01781 · Cited by 217 · see citing works

Small‐Molecule Stabilization of Protein–Protein Interactions: An Underestimated Concept in Drug Discovery?

Thiel, P., Kaiser, M., & Ottmann, C. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201107616 · Cited by 207 · see citing works

Dissecting Fragment-Based Lead Discovery at the von Hippel-Lindau Protein:Hypoxia Inducible Factor 1α Protein-Protein Interface

Molle, I. V., Thomann, A., Buckley, D. L., So, E. C., Lang, S., Crews, C. M., & Ciulli, A. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.08.015 · Cited by 198 · see citing works

Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase: Structure–Activity Relationships Leading to the Chemical Probe (2 S ,4 R )-1-(( S )-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy- N -(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298)

Soares, P., Gadd, M. S., Frost, J., Galdeano, C., Ellis, L. C. J., Epemolu, O., Rocha, S., Read, K. D., & Ciulli, A. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00675 · Cited by 180 · see citing works

Design, synthesis and biological evaluation of nuclear receptor-degradation inducers

Itoh, Y., Kitaguchi, R., Ishikawa, M., Naito, M., & Hashimoto, Y. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.09.041 · Cited by 142 · see citing works

X-ray analyses of peptide–inhibitor complexes define the structural basis of specificity for human and mouse renins

Dhanaraj, V., Dealwis, C. G., Frazão, C., Badasso, M. O., Sibanda, B. L., Tickle, I. J., Cooper, J. B., DRIESSEN, H. P. C., Newman, M., Aguilar, C. F., et al. (1992) · Nature · doi:10.1038/357466a0 · Cited by 140 · see citing works

COMPOUNDS DESIGNED TO FIT A SITE OF KNOWN STRUCTURE IN HUMAN HAEMOGLOBIN

Beddell, C. R., Goodford, P. J., Norrington, F. E. A., Wilkinson, S., & Wootton, R. (1976) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1976.tb07468.x · Cited by 131 · see citing works

Thalidomide as an emerging immunotherapeutic agent

Marriott, J. B., Muller, G. W., & Dalgleish, A. G. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01531-5 · Cited by 125 · see citing works

The crystal structures of recombinant glycosylated human renin alone and in complex with a transition state analog inhibitor

Rahuel, J. (1991) · Journal of Structural Biology · doi:10.1016/1047-8477(91)90048-2 · Cited by 122 · see citing works

Recognition of substrate degrons by E3 ubiquitin ligases and modulation by small-molecule mimicry strategies

Lucas, X., & Ciulli, A. (2017) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.12.015 · Cited by 92 · see citing works

Jostling for Position: Optimizing Linker Location in the Design of Estrogen Receptor‐Targeting PROTACs

Cyrus, K., Wehenkel, M., Choi, E., Lee, H., Swanson, H. I., & Kim, K. (2010) · ChemMedChem · doi:10.1002/cmdc.201000146 · Cited by 91 · see citing works

Protein crystallography and drug discovery: recollections of knowledge exchange between academia and industry

Blundell, T. L. (2017) · IUCrJ · doi:10.1107/s2052252517009241 · Cited by 81 · see citing works

SPLINTS: small-molecule protein ligand interface stabilizers

Fischer, E. S., Park, E., Eck, M. J., & Thomä, N. H. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.01.004 · Cited by 39 · see citing works

The art and practice of structure-based drug design: A molecular modeling perspective

(1996) · doi:10.1002/(sici)1098-1128(199601)16:1

PROTAC targeted protein degraders: the past is prologue

Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395 · see citing works

PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future

Pettersson, M., & Crews, C. M. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2019.01.002 · Cited by 818 · see citing works

Exploring the next generation of antibody–drug conjugates

Tsuchikama, K., Anami, Y., Ha, S. Y. Y., & Yamazaki, C. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00850-2 · Cited by 659 · see citing works

PROTACs: great opportunities for academia and industry

Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y.-G., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 651 · see citing works

BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design

Farnaby, W., Koegl, M., Roy, M. J., Whitworth, C., Diers, E., Trainor, N., Zollman, D., Steurer, S., Karolyi-Oezguer, J., Riedmueller, C., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0294-6 · Cited by 562 · see citing works

Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase

Smith, B. E., Wang, S. L., Jaime-Figueroa, S., Harbin, A., Wang, J., Hamman, B. D., & Crews, C. M. (2019) · Nature Communications · doi:10.1038/s41467-018-08027-7 · Cited by 517 · see citing works

Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16

Zhang, X., Crowley, V. M., Wucherpfennig, T. G., Dix, M. M., & Cravatt, B. F. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0279-5 · Cited by 487 · see citing works

Harnessing the anti-cancer natural product nimbolide for targeted protein degradation

Spradlin, J. N., Hu, X., Ward, C. C., Brittain, S. M., Jones, M. D., Ou, L., To, M., Proudfoot, A., Ornelas, E., Woldegiorgis, M., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0304-8 · Cited by 432 · see citing works

Current strategies for the design of PROTAC linkers: a critical review

Troup, R. I., Fallan, C., & Baud, M. G. J. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00018 · Cited by 424 · see citing works

SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate

Roy, M. J., Winkler, S., Hughes, S. J., Whitworth, C., Galant, M., Farnaby, W., Rumpel, K., & Ciulli, A. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00092 · Cited by 386 · see citing works

Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel–Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7

Zoppi, V., Hughes, S. J., Maniaci, C., Testa, A., Gmaschitz, T., Wieshofer, C., Koegl, M., Riching, K. M., Daniels, D. L., Spallarossa, A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01413 · Cited by 336 · see citing works

Target and tissue selectivity of PROTAC degraders

Guenette, R. G., Yang, S. W., Min, J., Pei, B., & Potts, P. R. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00200k · Cited by 324 · see citing works

Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action

Riching, K. M., Mahan, S. D., Corona, C. R., McDougall, M. G., Vasta, J. D., Robers, M. B., Urh, M., & Daniels, D. L. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00692 · Cited by 307 · see citing works

Chemistries of bifunctional PROTAC degraders

Cao, C., He, M., Wang, L., He, Y., & Rao, Y. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00220e · Cited by 313 · see citing works

Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges

Zeng, S., Huang, W., Zheng, X., Cheng, L., Zhang, Z., Wang, J., & Shen, Z. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112981 · Cited by 262 · see citing works

Structure‐Based Design of a Macrocyclic PROTAC

Testa, A., Hughes, S. J., Lucas, X., Wright, J. E., & Ciulli, A. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201914396 · Cited by 251 · see citing works

Unraveling the Role of Linker Design in Proteolysis Targeting Chimeras

Bemis, T. A., Clair, J. J. L., & Burkart, M. D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00482 · Cited by 244 · see citing works

Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity

Imaide, S., Riching, K. M., Makukhin, N., Vetma, V., Whitworth, C., Hughes, S. J., Trainor, N., Mahan, S. D., Murphy, N., Cowan, A. D., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00878-4 · Cited by 251 · see citing works

Proteolysis‐targeting chimeras in drug development: A safety perspective

Moreau, K., Coen, M., Zhang, A. X., Pachl, F., Castaldi, M. P., Dahl, G., Boyd, H., Scott, C., & Newham, P. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15014 · Cited by 229 · see citing works

PRosettaC: Rosetta Based Modeling of PROTAC Mediated Ternary Complexes

Zaidman, D., Prilusky, J., & London, N. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00589 · Cited by 224 · see citing works

Proximity-Based Modalities for Biology and Medicine

Liu, X., & Ciulli, A. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00395 · Cited by 205 · see citing works

From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation

Cecchini, C., Pannilunghi, S., Tardy, S., & Scapozza, L. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.672267 · Cited by 198 · see citing works

<i>In Silico</i> Modeling of PROTAC-Mediated Ternary Complexes: Validation and Application

Drummond, M. L., & Williams, C. I. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00872 · Cited by 199 · see citing works

Rational Chemical Design of Molecular Glue Degraders

Toriki, E. S., Papatzimas, J. W., Nishikawa, K., Dovala, D., Frank, A. O., Hesse, M. J., Danková, D., Song, J.-G., Bruce-Smythe, M., Struble, H., et al. (2023) · ACS Central Science · doi:10.1021/acscentsci.2c01317 · Cited by 196 · see citing works

Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders

Yang, J., Li, Y., Aguilar, A., Liu, Z., Yang, C.-Y., & Wang, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00846 · Cited by 190 · see citing works

The roles of E3 ubiquitin ligases in cancer progression and targeted therapy

Sampson, C., Wang, Q., Otkur, W., Zhao, H., Lu, Y., Liu, X., & Piao, H. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1204 · Cited by 186 · see citing works

Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820

Du, X., Volkov, O. A., Czerwinski, R. M., Tan, H., Huerta, C., Morton, E. R., Rizzi, J. P., Wehn, P. M., Xu, R., Nijhawan, D., et al. (2019) · Structure · doi:10.1016/j.str.2019.10.005 · Cited by 181 · see citing works

SNIPERs—Hijacking IAP activity to induce protein degradation

Naito, M., Ohoka, N., & Shibata, N. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2018.12.002 · Cited by 167 · see citing works

PROTACs– a game-changing technology

Konstantinidou, M., Li, J., Zhang, B., Wang, Z., Shaabani, S., ter Brake, F., Essa, K., & Dömling, A. S. S. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1659242 · Cited by 167 · see citing works

Homo-PROTACs for the Chemical Knockdown of Cereblon

Steinebach, C., Lindner, S., Udeshi, N. D., Mani, D. R., Kehm, H., Köpff, S., Carr, S. A., Gütschow, M., & Krönke, J. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00693 · Cited by 160 · see citing works

Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta

Bai, N., Miller, S. A., Andrianov, G. V., Yates, M., Kirubakaran, P., & Karanicolas, J. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01451 · Cited by 157 · see citing works

Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs

Girardini, M., Maniaci, C., Hughes, S. J., Testa, A., & Ciulli, A. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.02.048 · Cited by 157 · see citing works

Amide-to-Ester Substitution as a Strategy for Optimizing PROTAC Permeability and Cellular Activity

Klein, V. G., Bond, A. G., Craigon, C., Lokey, R. S., & Ciulli, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01496 · Cited by 152 · see citing works

3-Fluoro-4-hydroxyprolines: Synthesis, Conformational Analysis, and Stereoselective Recognition by the VHL E3 Ubiquitin Ligase for Targeted Protein Degradation

Testa, A., Lucas, X., Castro, G. V., Chan, K.-H., Wright, J. E., Runcie, A. C., Gadd, M. S., Harrison, W. T. A., Ko, E. J., Fletcher, D., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b05807 · Cited by 144 · see citing works

Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions

Popow, J., Arnhof, H., Bader, G., Berger, H., Ciulli, A., Covini, D., Dank, C., Gmaschitz, T., Greb, P., Karolyi-Özguer, J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01826 · Cited by 138 · see citing works

Targeted Degradation of a Hypoxia-Associated Non-coding RNA Enhances the Selectivity of a Small Molecule Interacting with RNA

Costales, M. G., Suresh, B. M., Vishnu, K., & Disney, M. D. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.04.008 · Cited by 132 · see citing works

Targeted protein degradation and the enzymology of degraders

Fisher, S. L., & Phillips, A. J. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.05.004 · Cited by 126 · see citing works

Structure-based drug design: aiming for a perfect fit

van Montfort, R. L. M., & Workman, P. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170052 · Cited by 127 · see citing works

Manumycin polyketides act as molecular glues between UBR7 and P53

Isobe, Y., Okumura, M., McGregor, L. M., Brittain, S. M., Jones, M. D., Liang, X., White, R., Forrester, W., McKenna, J. M., Tallarico, J. A., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0557-2 · Cited by 124 · see citing works

PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes

Smalley, J. P., Adams, G. E., Millard, C. J., Song, Y., Norris, J. K. S., Schwabe, J. W. R., Cowley, S. M., & Hodgkinson, J. T. (2020) · Chemical Communications · doi:10.1039/d0cc01485k · Cited by 121 · see citing works

Bivalent Ligands for Protein Degradation in Drug Discovery

Scheepstra, M., Hekking, K. F. W., Hijfte, L. V., & Folmer, R. H. A. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.01.006 · Cited by 120 · see citing works

PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy

Kelm, J. M., Pandey, D. S., Malin, E., Kansou, H. W., Arora, S., Kumar, R., & Gavande, N. S. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01707-5 · Cited by 115 · see citing works

Targeted protein acetylation in cells using heterobifunctional molecules

Wang, W. W., Chen, L.-Y., Wozniak, J. M., Jadhav, A. M., Anderson, H., Malone, T. E., & Parker, C. G. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c07850 · Cited by 114 · see citing works

Site-Directed Fragment-Based Screening for the Discovery of Protein–Protein Interaction Stabilizers

Sijbesma, E., Hallenbeck, K. K., Leysen, S., de Vink, P. J., Skóra, L., Jahnke, W., Brunsveld, L., Arkin, M. R., & Ottmann, C. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b11658 · Cited by 112 · see citing works

The importance of cellular degradation kinetics for understanding mechanisms in targeted protein degradation

Riching, K. M., Caine, E. A., Urh, M., & Daniels, D. L. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00339b · Cited by 105 · see citing works

From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1)

Papatzimas, J. W., Gorobets, E., Maity, R., Muniyat, M. I., MacCallum, J. L., Neri, P., Bahlis, N. J., & Derksen, D. J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00455 · Cited by 103 · see citing works

DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance

Schröder, M., Renatus, M., Liang, X., Meili, F., Zoller, T., Ferrand, S., Gauter, F., Li, X., Sigoillot, F. D., Gleim, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44237-4 · Cited by 108 · see citing works

Bifunctional chemical probes inducing protein–protein interactions

Maniaci, C., & Ciulli, A. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.07.003 · Cited by 100 · see citing works

Predicting the structural basis of targeted protein degradation by integrating molecular dynamics simulations with structural mass spectrometry

Dixon, T. J., MacPherson, D. J., Mostofian, B., Dauzhenka, T. A., Lotz, S., McGee, T. D., Shechter, S., Shrestha, U. R., Wiewiora, R., McDargh, Z. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33575-4 · Cited by 100 · see citing works

Covalent Small Molecules as Enabling Platforms for Drug Discovery

Dalton, S. E., & Campos, S. (2019) · ChemBioChem · doi:10.1002/cbic.201900674 · Cited by 98 · see citing works

Biolayer interferometry and its applications in drug discovery and development

Jug, A., Bratkovič, T., & Ilaš, J. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117741 · Cited by 97 · see citing works

Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader

Tovell, H., Testa, A., Zhou, H., Shpiro, N., Crafter, C., Ciulli, A., & Alessi, D. R. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00505 · Cited by 95 · see citing works

Regulated induced proximity targeting chimeras—RIPTACs—A heterobifunctional small molecule strategy for cancer selective therapies

Raina, K., Forbes, C. D., Stronk, R., Rappi, J. P., Eastman, K. J., Zaware, N., Yu, X., Li, H., Bhardwaj, A., Gerritz, S. W., et al. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.07.005 · Cited by 121 · see citing works

Proteolysis targeting chimeras (PROTACs) in cancer therapy

Ocaña, A., & Pandiella, A. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01672-1 · Cited by 87 · see citing works

A proximity biotinylation-based approach to identify protein-E3 ligase interactions induced by PROTACs and molecular glues

Yamanaka, S., Horiuchi, Y., Matsuoka, S., Kido, K., Nishino, K., Maeno, M., Shibata, N., Kosako, H., & Sawasaki, T. (2022) · Nature Communications · doi:10.1038/s41467-021-27818-z · Cited by 86 · see citing works

Mechanism of degrader-targeted protein ubiquitinability

Crowe, C., Nakasone, M. A., Chandler, S., Craigon, C., Sathe, G. J., Tatham, M. H., Makukhin, N., Hay, R. T., & Ciulli, A. (2024) · Science Advances · doi:10.1126/sciadv.ado6492 · Cited by 81 · see citing works

Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs

Bai, N., Riching, K. M., Makaju, A., Wu, H., Acker, T. M., Ou, S.-C., Zhang, Y., Shen, X., Bulloch, D. N., Rui, H., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101653 · Cited by 77 · see citing works

Recent Advances in PROTACs for Drug Targeted Protein Research

Yao, T., Xiao, H., Wang, H., & Xu, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810328 · Cited by 78 · see citing works

Assays and Technologies for Developing Proteolysis Targeting Chimera Degraders

Liu, X., Zhang, X., Lv, D., Yuan, Y., Zheng, G., & Zhou, D. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0073 · Cited by 73 · see citing works

Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs

Anderson, N. A., Cryan, J., Ahmed, A., Dai, H., McGonagle, G. A., Rozier, C., & Benowitz, A. B. (2020) · Bioorganic &amp; Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127106 · Cited by 69 · see citing works

Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods

Mostofian, B., Martin, H., Razavi, A. M., Patel, S., Allen, B. K., Sherman, W., & Izaguirre, J. A. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00603 · Cited by 68 · see citing works

Monitoring and deciphering protein degradation pathways inside cells

Daniels, D. L., Riching, K. M., & Urh, M. (2018) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2018.12.001 · Cited by 68 · see citing works

A Versatile and Sustainable Multicomponent Platform for the Synthesis of Protein Degraders: Proof-of-Concept Application to BRD4-Degrading PROTACs

Bhela, I. P., Ranza, A., Balestrero, F. C., Serafini, M. T., Aprile, S., Martino, R. M. C. D., Condorelli, F., & Pirali, T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01218 · Cited by 67 · see citing works

Native Mass Spectrometry Can Effectively Predict PROTAC Efficacy

Beveridge, R., Kessler, D., Rumpel, K., Ettmayer, P., Meinhart, A., & Clausen, T. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00049 · Cited by 67 · see citing works

Proteomic approaches advancing targeted protein degradation

Sathe, G. J., & Sapkota, G. P. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.08.007 · Cited by 64 · see citing works

Identification and Characterization of a Novel Brain-Penetrant Indoleamine 2,3 Dioxygenase 1 Protein Degrader for Glioblastoma

Bollu, L. R., Bommi, P. V., Monsen, P. J., Zhai, L., Lauing, K. L., Bell, A., Kim, M., Ladomersky, E., Yang, X., Platanias, L. C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00771 · Cited by 62 · see citing works

Proteolysis targeting chimeras (PROTACs) for epigenetics research

Vogelmann, A., Robaa, D., Sippl, W., & Jung, M. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.01.010 · Cited by 59 · see citing works

Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines

Nishiguchi, G., Mascibroda, L. G., Young, S. M., Caine, E. A., Abdelhamed, S., Kooijman, J. J., Miller, D. J., Das, S., McGowan, K., Mayasundari, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44698-1 · Cited by 57 · see citing works

Molecular design opportunities presented by solvent‐exposed regions of target proteins

Jiang, X., Yu, J. H., Zhou, Z., Kongsted, J., Song, Y., Pannecouque, C. C., Clercq, E. D., Kang, D., Poongavanam, V., Liu, X., et al. (2019) · Medicinal Research Reviews · doi:10.1002/med.21581 · Cited by 57 · see citing works

Reversible Covalent Imine-Tethering for Selective Stabilization of 14-3-3 Hub Protein Interactions

Cossar, P. J., Wolter, M., Dijck, L. V., Valenti, D., Levy, L. M., Ottmann, C., & Brunsveld, L. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c03035 · Cited by 56 · see citing works

Bifunctional modalities for repurposing protein function

Modell, A. E., Lai, S., Nguyen, T. M., & Choudhary, A. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.06.005 · Cited by 54 · see citing works

A critical evaluation of the approaches to targeted protein degradation for drug discovery

Chopra, R., Sadok, A., & Collins, I. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.02.002 · Cited by 53 · see citing works

Profiling of diverse tumor types establishes the broad utility of VHL-based ProTaCs and triages candidate ubiquitin ligases

Luo, X., Archibeque, I., Dellamaggiore, K., Smither, K., Homann, O. R., Lipford, J. R., & Mohl, D. A. (2022) · iScience · doi:10.1016/j.isci.2022.103985 · Cited by 53 · see citing works

Cyclic peptides can engage a single binding pocket through highly divergent modes

Patel, K., Walport, L. J., Walshe, J. L., Solomon, P. D., Low, J. K. K., Tran, D. H., Mouradian, K. S., Silva, A. P. G., Wilkinson‐White, L. E., Norman, A. R., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003086117 · Cited by 51 · see citing works

Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities

Maity, P., Chatterjee, J., Patil, K. T., Arora, S., Katiyar, M. K., Kumar, M., Samarbakhsh, A., Joshi, G., Bhutani, P., Chugh, M., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01242 · Cited by 51 · see citing works

USP7 as an emerging therapeutic target: A key regulator of protein homeostasis

Guo, N.-J., Wang, B., Zhang, Y., Kang, H., Nie, H., Feng, M.-K., Zhang, X.-Y., Zhao, L., Wang, N., Liu, H., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130309 · Cited by 50 · see citing works

Fragment-based Differential Targeting of PPI Stabilizer Interfaces

Guillory, X., Wolter, M., Leysen, S., Neves, J. F., Kuusk, A., Genet, S. A. A. M., Somsen, B. A., Morrow, J. K., Rivers, E. L., van Beek, L., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01942 · Cited by 49 · see citing works

Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer

Wang, C., Wang, H., Zheng, C., Liu, Z., Gao, X., Xu, F., Niu, Y., Zhang, L., & Xu, P. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113386 · Cited by 49 · see citing works

Molecular glues to stabilise protein–protein interactions

Soini, L., Leysen, S., Davis, J., & Ottmann, C. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102169 · Cited by 49 · see citing works

Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy

Bhole, R. P., Kute, P. R., Chikhale, R. V., Bonde, C. G., Pant, A. M., & Gurav, S. S. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106720 · Cited by 48 · see citing works

CDK Family PROTAC Profiling Reveals Distinct Kinetic Responses and Cell Cycle–Dependent Degradation of CDK2

Riching, K. M., Schwinn, M. K., Vasta, J. D., Robers, M. B., Machleidt, T., Urh, M., & Daniels, D. L. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220973602 · Cited by 46 · see citing works

Targeted AURKA degradation: Towards new therapeutic agents for neuroblastoma

Rishfi, M., Krols, S., Martens, F., Bekaert, S.-L., Sanders, E., Eggermont, A., Vloed, F. D., Goulding, J. R., Risseeuw, M., Molenaar, J. J., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115033 · Cited by 45 · see citing works

Targeted protein degradation mechanisms

Zhang, Y., Loh, C., Chen, J., & Mainolfi, N. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2019.01.001 · Cited by 45 · see citing works

Advances in molecular glues: exploring chemical space and design principles for targeted protein degradation

Kumar, S., Venkatachalapathy, M., Sistla, R. K., & Poongavanam, V. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104205 · Cited by 43 · see citing works

Structural insights into substrate recognition by the SOCS2 E3 ubiquitin ligase

Kung, W.-W., Ramachandran, S., Makukhin, N., Bruno, E., & Ciulli, A. (2019) · Nature Communications · doi:10.1038/s41467-019-10190-4 · Cited by 41 · see citing works

Native Mass Spectrometry for the Study of PROTAC GNE‐987‐Containing Ternary Complexes

Sternicki, L. M., Nonomiya, J., Liu, M., Mulvihill, M. M., & Quinn, R. J. (2021) · ChemMedChem · doi:10.1002/cmdc.202100113 · Cited by 40 · see citing works

Protein–protein interactions: developing small-molecule inhibitors/stabilizers through covalent strategies

Lucero, B., Francisco, K. R., Liu, L. J., Caffrey, C. R., & Ballatore, C. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.04.007 · Cited by 39 · see citing works

The current status and future prospects for therapeutic targeting of KEAP1-NRF2 and β-TrCP-NRF2 interactions in cancer chemoresistance

Srivastava, R., Fernández-Ginés, R., Encinar, J. A., Cuadrado, A., & Wells, G. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.09.023 · Cited by 39 · see citing works

PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer

Khan, S. U., Cao, L. S., Wiegand, J. S., Zhang, P., Zajac‐Kaye, M., Kaye, F. J., Zheng, G., & Zhou, D. (2024) · Cells · doi:10.3390/cells13060528 · Cited by 40 · see citing works

Fluorescence Anisotropy-Based Tethering for Discovery of Protein–Protein Interaction Stabilizers

Sijbesma, E., Somsen, B. A., Miley, G. P., de Gevel, I. A. L.-V., Brunsveld, L., Arkin, M. R., & Ottmann, C. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00646 · Cited by 38 · see citing works

A kinetic proofreading model for bispecific protein degraders

Bartlett, D. W., & Gilbert, A. M. (2020) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-020-09722-z · Cited by 37 · see citing works

PROTAC: targeted drug strategy. Principles and limitations

Koroleva, O. A., Dutikova, Y. V., Trubnikov, A. V., Zenov, F. A., Manasova, E. V., Shtil, A. A., & Kurkin, A. V. (2022) · Russian Chemical Bulletin · doi:10.1007/s11172-022-3659-z · Cited by 38 · see citing works

Molecular glue degraders: exciting opportunities for novel drug discovery

Lemaitre, T., Cornu, M., Schwalen, F., Since, M., Kieffer, C., & Voisin-Chiret, A. S. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2306845 · Cited by 36 · see citing works

Automated Design of Macrocycles for Therapeutic Applications: From Small Molecules to Peptides and Proteins

Sindhikara, D., Wagner, M., Gkeka, P., Güssregen, S., Tiwari, G., Heßler, G., Yapici, E., Li, Z., & Evers, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01500 · Cited by 35 · see citing works

High-Throughput Quantitative Assay Technologies for Accelerating the Discovery and Optimization of Targeted Protein Degradation Therapeutics

Simard, J. R., Lee, L., Vieux, E. F., Improgo, R., Tieu, T. N., Phillips, A. J., Fisher, S. L., Pollock, R. M., & Park, E. Y. (2021) · SLAS DISCOVERY · doi:10.1177/2472555220985049 · Cited by 34 · see citing works

Regulated Induced Proximity Targeting Chimeras (RIPTACs): a Novel Heterobifunctional Small Molecule Therapeutic Strategy for Killing Cancer Cells SelectivelyPreprint

Raina, K., Forbes, C. D., Stronk, R., Rappi, J. P., Eastman, K. J., Gerritz, S. W., Yu, X., Li, H., Bhardwaj, A., Forgione, M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.01.522436 · Cited by 34 · see citing works

Development of a Hematopoietic Prostaglandin D Synthase-Degradation Inducer

Yokoo, H., Shibata, N., Naganuma, M., Murakami, Y., Fujii, K., Ito, T., Aritake, K., Naito, M., & Demizu, Y. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00605 · Cited by 33 · see citing works

Mathematical Model for Covalent Proteolysis Targeting Chimeras: Thermodynamics and Kinetics Underlying Catalytic Efficiency

Chaudhry, C. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02076 · Cited by 33 · see citing works

Target protein degradation by protacs: A budding cancer treatment strategy

Choudhary, D., Kaur, A., Singh, P., Chaudhary, G., Kaur, R., Bayan, M. F., Chandrasekaran, B., Marji, S. M., & Ayman, R. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108525 · Cited by 31 · see citing works

PROTACs technology for targeting non-oncoproteins: Advances and perspectives

Wang, C., Zhang, Y., Xing, D., & Zhang, R. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105109 · Cited by 31 · see citing works

Structural and Biophysical Principles of Degrader Ternary Complexes

Zollman, D., & Ciulli, A. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160691-00014 · Cited by 3 · see citing works

Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation

Wurz, R. P., Rui, H., Dellamaggiore, K., Ghimire-Rijal, S., Choi, K., Smither, K., Amegadzie, A. K., Chen, N., Li, X., Banerjee, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39904-5 · Cited by 151 · see citing works

Targeted protein degradation in the digital era: Computational challenges and opportunities for PROTACs

Tewari, A., Pawar, A. B., & Roy, S. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100372

Techniques for Accelerating the Understanding of PROTAC-Based Ternary Complex

Ullah, I., Gao, J., & Yuan, Y. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_840

Induced Proximity Beyond PROTACs: Computational Discovery of Molecular Glues, Degrader Mechanisms, Ternary Complexes, and Emerging Therapeutic Modalities

Dupuis, C., Perrin, H., Morel, E., & Martin, T. (2026) · International Journal of Pharmaceutical and Phytopharmacological Research · doi:10.51847/eweh2fzfsy